Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Bachem invested in a capacity expansion for large-scale production of oligonucleotide APIs
Released By Bachem
October 21, 2022
Bachem, the Swiss pharmaceutical company, invested in a capacity expansion for large-scale production of oligonucleotide active pharmaceutical ingredients (APIs). Each step within the company’s oligonucleotide manufacturing process uses unique, innovative equipment to deliver the highest-quality products and to increase sustainability. Tailor-made oligonucleotide synthesisers To ensure only the highest-quality oligonucleotide is supplied to customers, Bachem designed a large-scale oligonucleotide synthesiser. This synthesiser optimises the process of oligonucleotide synthesis and has been qualified for GMP batches from a 0.2 mol to 2 mol scale. One of the engineering solutions used for the innovative synthesiser is in-line mixing of dichloroacetic acid (DCA) and toluene. This solution is used as the initial step for all coupling cycles of oligonucleotide synthesis, deprotecting the 5’-dimethoxytrityl (DMT) group and releasing the 5’-hydroxy group to ensure the coupling reaction takes place. For the majority of synthesisers, the percentage of DCA in toluene is fixed, whereas Bachem’s new skid has a possibility to change the ratio of DCA (usually between 3% to 10%). This ability to change the concentration is highly beneficial, since using too much DCA can cause undesired side reactions and decrease API quality. In addition, Bachem has also introduced further innovative customisations to optimise oligonucleotide synthesis. These new customisations aim to provide a more efficient process that will consistently produce high-quality crude API. Firstly, a heat exchanger has been added to enable full temperature control, maintaining the optimal conditions for deprotection and coupling. The synthesiser also features dynamic axial columns (DAC) which contain a piston that moves throughout each synthesis cycle of the process. This piston allows full control of the column’s volume, avoiding dead volume and optimising the amount of solvent required. Automated C&D equipment After synthesis has taken place, an oligonucleotide has to undergo a process of cleaving and deprotection (C&D). To improve efficiency, Bachem has equipped their oligonucleotide production line with an automated, large-scale C&D system which uses a two-step process. Once the synthesis is complete, and the same column has been installed onto the C&D skid, the first step is to deprotect the cyanoethyl groups before the cleavage of the oligonucleotide from its solid support. Importantly, a solution of room temperature ammonia is able to circulate throughout the column of a given volume. This solution carries the released oligonucleotide to the collector vessel, which is made from Hastelloy®, providing resistance against highly-corrosive solutions. The second step of the process is the deprotection of the protecting groups from the oligonucleotide. Once the ammonia solution has recirculated several times between the vessel and the column, all the oligonucleotide is cleaved from its support before it’s collected in the vessel. The vessel is then closed and heated under pressure with the ammonia solution, using a unique automated temperature feature. And if other deprotection solutions are required, Bachem’s C&D machine is also equipped with a multi-port inlet. After the C&D step has been completed, the oligonucleotide is free from the support and protecting groups, meaning the crude API is ready for ultrafiltration. Continuous chromatography for oligonucleotide purification To further optimise the process of oligonucleotide manufacturing, Bachem has set up the first continuous chromatography equipment for use at an industrial scale. Through enabling continuous recycling of side-cuts (mixed fractions of impurities and API), solvent consumption can be decreased by more than 30% compared to single-column batch purification. This innovative Multicolumn Countercurrent Solvent Gradient Purification (MCSGP) technology therefore improves sustainability during this important step. In addition, this technology is also cost-effective and substantially reduces waste. MCSGP runs continuously, providing high product yield without negatively impacting purity, whilst allowing room for additional savings in cycle time. These savings in cycle time can reach up to 70%, compared to other batch chromatography methods. The unique, custom-built synthesiser, C&D system and MCSGP equipment will all enhance the quality, sustainability and cost-effectiveness of oligonucleotide API production. About Bachem Bachem is a leading, innovation-driven company specialising in the development and manufacture of peptides and oligonucleotides. With 50 years of experience, Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally, with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !